Home » Stocks » IBIO

iBio, Inc. (IBIO)

Stock Price: $1.82 USD 0.06 (3.13%)
Updated Mar 1, 2021 3:25 PM EST - Market open
Market Cap 380.18M
Revenue (ttm) 2.33M
Net Income (ttm) -24.14M
Shares Out 188.09M
EPS (ttm) -0.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $1.82
Previous Close $1.76
Change ($) 0.06
Change (%) 3.13%
Day's Open 1.83
Day's Range 1.78 - 1.87
Day's Volume 4,808,477
52-Week Range 0.76 - 7.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 5 days ago

These penny stocks are companies that have a crucial year ahead in terms of industry turnaround or company specific product development. The post 7 Penny Stocks In a Make-or-Break Year appeare...

Other stocks mentioned: BORR, EVFM, KSHB, OILFF, SB, TMBR
InvestorPlace - 1 week ago

With iBio making key executive-level appointments and recording excellent fiscal stats, IBIO stock's value proposition is hard to ignore. The post Hold iBio Shares as Q2 Highlights Strong Prod...

Benzinga - 1 week ago

iBio (NYSE: IBIO) shares are trading lower Wednesday after the company reported second-quarter earnings results. iBio's main area of business is plant-based protein expression technologies for...

Other stocks mentioned: BHC, DMAC, ONCY, OTLK
GlobeNewsWire - 1 week ago

BRYAN, Tx., Feb. 16, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its fina...

InvestorPlace - 2 weeks ago

In the midst of an expensive market, traders are turning to penny stocks as a cheaper alternative. But avoid these seven risky penny names.

Other stocks mentioned: CTRM, GNUS, NAK, NAKD, SNDL, UXIN
GlobeNewsWire - 2 weeks ago

BRYAN, Texas, Feb. 09, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that i...

InvestorPlace - 3 weeks ago

Ibio (IBIO) stock is on the rise Thursday despite a lack of news coming out today that would result in the movement today. The post IBIO Stock: 5 Things for Investors to Know About iBio Today ...

OTC PR Wire - 3 weeks ago

If January is a sign of things to come for 2021, traders and investors are going to make a lot of money this year. 4 penny stocks on the move are Anavex Life Sciences (NASDAQ: AVXL), iBio Inc ...

InvestorPlace - 1 month ago

We may be seeing some sector rotation, and many companies that have made big moves in recent weeks have stocks under $10. The post 7 Stocks Under $10 to Buy for February  appeared first on Inv...

Other stocks mentioned: CRNT, FINV, HIMX, KOPN, RBBN, STON
The Motley Fool - 1 month ago

One analyst says investors are underappreciating the biotech's growth prospects.

InvestorPlace - 1 month ago

Shares of IBIO stock are taking off on Friday after an analyst from Cantor Fitzgerald initiated an Overweight rating and $3 price target. The post IBIO Stock Alert: Analyst Call Sends Shares o...

The Motley Fool - 2 months ago

Innovation paid off big for investors.

Other stocks mentioned: AQB, CTIC, ALPN
InvestorPlace - 2 months ago

Obviously, we'll never forget this tumultuous year. During a calendar full of pandemic panic, economic crisis and social unrest, here are my best calls (and worst calls) of 2020.

Other stocks mentioned: BGFV, BYND, CWH, F, GME, MMEDF, NKLA
GlobeNewsWire - 2 months ago

BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the ap...

InvestorPlace - 2 months ago

It's the time to clean house and make portfolio space for stronger investment opportunities during 2021. Here are 7 stocks to sell.

Other stocks mentioned: HOG, INTC, WFC, HTZGQ, LKNCY, SOLO
InvestorPlace - 2 months ago

Value stocks are surging lately. That's caused many penny stocks to roar back to life.

Other stocks mentioned: HOFV, NAK, SPG, WPG, WTER, CHK
GlobeNewsWire - 2 months ago

BRYAN, Texas, Dec. 10, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the cl...

InvestorPlace - 2 months ago

IBIO stock remains volatile as the company continues its focus on a breakthrough product to combat the coronavirus pandemic. The post Be Wary as iBio Seeks a Place in the Vaccine Game appeared...

The Motley Fool - 2 months ago

This can happen when a company holds out its hand for a big chunk of fresh capital.

Other stocks mentioned: ARCT, MRNS
Benzinga - 2 months ago

iBio (NYSE: IBIO) shares are trading lower on Tuesday after the company announced a common stock offering. iBio's main area of business is plant-based protein expression technologies for vacci...

Other stocks mentioned: CMD, STRO
InvestorPlace - 2 months ago

Investors bought the Covid-19 hype in IBIO stock. With little progress made, however, reality is setting in, which means the fade should continue.

InvestorPlace - 2 months ago

The IBIO stock price is down, but that doesn't mean the company's in trouble. In fact, the data shows that iBio's fiscal health is improving.

GlobeNewsWire - 2 months ago

BRYAN, Texas, Dec. 08, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the pr...

InvestorPlace - 2 months ago

While its shot at pioneering a novel coronavirus vaccine has passed, iBio and its IBIO stock could benefit from other medical breakthroughs. The post Why iBio Remains Worth a Look In a Post-Pa...

GlobeNewsWire - 2 months ago

BRYAN, Texas, Dec. 07, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced an und...

InvestorPlace - 2 months ago

Biotech innovator IBIO stock has been tossed around based on iBio's COVID-19 vaccine progress, but its FastPharma tech is the long-term play. The post Biotech Innovator IBIO Is Down, but Not O...

InvestorPlace - 2 months ago

Ibio (IBIO) is seeing shares of IBIO stock soar higher on Wednesday following news of a contract for the biotech company. The post iBio News: Why IBIO Stock Is Soaring 16% Today appeared first...

GlobeNewsWire - 2 months ago

BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract development and manufacturing organization (“CDMO”...

InvestorPlace - 3 months ago

iBio has a long-standing relationship with the United States defense industry. But that hasn't enough to give IBIO stock a leg up in the Covid-19 race.

Insider Monkey - 3 months ago

Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend mi...

InvestorPlace - 3 months ago

One of the more intriguing high-risk, high-reward ideas in the Covid-19 space, IBIO stock had an opportunity to distinguish itself. But with the vaccine race heating up, the dangers outweigh t...

GlobeNewsWire - 3 months ago

- Methods for Production in iBio's FastPharming® System Foundational to Antifibrotic Development Program - - Methods for Production in iBio's FastPharming® System Foundational to Antifibrotic ...

InvestorPlace - 3 months ago

iBio reports impressive Q1 results as biotech companies see a strong rally this year. Here's the latest on IBIO stock.

InvestorPlace - 3 months ago

iBio's first-quarter included steep losses and not much else. If IBIO stock is to rise to $2, investors need some good news to chew on.

InvestorPlace - 3 months ago

The latest in IBIO news: stay away from IBIO stock, which has over-issued shares to survive. The stock remains below the average issue price.

Seeking Alpha - 3 months ago

iBio, Inc. (iBio) CEO Thomas Isett on Q1 2021 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

BRYAN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its fi...

InvestorPlace - 3 months ago

The latest iBio news isn't good. It's taken too long for IBIO to develop a coronavirus vaccine and now the opportunity has disappeared.

InvestorPlace - 3 months ago

iBio has a huge vertical farming facility and a couple of high-potential vaccine candidates, which should offer hope to IBIO stock holders. The post Two Covid-19 Vaccine Candidates Hold Promis...

InvestorPlace - 3 months ago

Investor interest a unique production system isn't enough to make buying IBIO stock a worthwhile move at this time. The post iBio Remains a Biotech Sideline Play as Covid Rages appeared first ...

GlobeNewsWire - 3 months ago

BRYAN, Texas, Nov. 05, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that i...

InvestorPlace - 3 months ago

IBIO stock has been hit hard by its apparent failure to produce the first COVID-19 vaccine, but that's a simplistic view of iBio's prospects. The post First to COVID-19 Vaccine or Not, iBio Is...

GlobeNewsWire - 3 months ago

- Brings >20 Years of Global Biotech Operations and Business Development Experience - - Brings >20 Years of Global Biotech Operations and Business Development Experience -

InvestorPlace - 4 months ago

Yes, I will continue to root for Ibio in its fight to make a huge leap with its Covid-19 efforts. But where my investment dollar is concerned, it'll be from the sidelines.

The Motley Fool - 4 months ago

The time to make money by investing in iBio is over. Here's why that's good news.

InvestorPlace - 4 months ago

With the viable candidate pool for novel coronavirus vaccines shrinking, this angle is probably closed to IBIO stock. However, speculators still have a shot with the therapeutic approach.

GlobeNewsWire - 4 months ago

- Adds More Than 25 Years of Financial Leadership in Pharma / Biotech to the Team - 

GlobeNewsWire - 4 months ago

- Senior Biopharm Executive with 20 Years of Immuno-Inflammatory Disease Therapeutic Experience -

GlobeNewsWire - 4 months ago

- Accomplished Biopharm Exec with Years of Clinical Experience in Respiratory Diseases -

InvestorPlace - 4 months ago

IBIO stock is a purely speculative bet compared to better options when it comes to investing in Covid-19 vaccine development. The post IBIO Remains a Purely Speculative Bet appeared first on I...

About IBIO

iBio, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; ... [Read more...]

Industry
Biotechnology
CEO
Thomas F. Isett III
Employees
43
Stock Exchange
NYSEAMERICAN
Ticker Symbol
IBIO
Full Company Profile

Financial Performance

In 2020, iBio, Inc.'s revenue was $1.64 million, a decrease of -18.83% compared to the previous year's $2.02 million. Losses were -$16.44 million, -6.56% less than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for iBio, Inc. stock is "Strong Buy" and the 12-month stock price forecast is 2.50.

Price Target
$2.50
Analyst Consensus: Strong Buy